Back to User profile » Dr Jason Bacharach
Papers published by Dr Jason Bacharach:
Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study
Bacharach J, Sadri E, Sawhney G, Kopczynski C, Merchea MM
Clinical Ophthalmology 2025, 19:175-186
Published Date: 21 January 2025
Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial [Corrigendum]
Bacharach J, Ahmed IIK, Sharpe ED, Korenfeld MS, Zhang S, Baudouin C
Clinical Ophthalmology 2023, 17:2763-2764
Published Date: 19 September 2023
Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial
Bacharach J, Ahmed IIK, Sharpe ED, Korenfeld MS, Zhang S, Baudouin C
Clinical Ophthalmology 2023, 17:2575-2588
Published Date: 1 September 2023
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI
Clinical Ophthalmology 2019, 13:215-216
Published Date: 24 January 2019
A Phase II /III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI
Clinical Ophthalmology 2018, 12:2637-2638
Published Date: 14 December 2018
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI
Clinical Ophthalmology 2018, 12:1921-1929
Published Date: 2 October 2018